CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Capex Y/Y Annual
Fibrogen Inc   (NASDAQ: FGEN)
Other Ticker:  
 
 

FGEN's Capital Expenditures Growth by Quarter and Year

Fibrogen Inc 's Capital Expenditures results by quarter and year

 



FGEN Capital Expenditures (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December - 0.14 0.25 0.33
3rd Quarter September - 0.08 0.68 0.87
2nd Quarter June - 0.01 0.99 0.91
1st Quarter March 0.02 0.03 0.59 1.64
FY   0.02 0.26 2.51 3.75

FGENs Annual Capital Expenditures
Fibrogen Inc 's Capital Expenditures in the fiscal year 2024 $ 0.27 millions
Fibrogen Inc 's Capital Expenditures in the fiscal year 2023 $ 2.52 millions
Fibrogen Inc 's Capital Expenditures in the fiscal year 2022 $ 3.74 millions
Fibrogen Inc 's Capital Expenditures in the fiscal year 2021 $ 5.19 millions
Fibrogen Inc 's Capital Expenditures in the fiscal year 2019 $ 5.76 millions




FGEN Capital Expenditures first quarter 2025 Y/Y Growth Comment
Fibrogen Inc reported drop in Capital Expenditures in the first quarter 2025 by -46.67% to $ 0.02 millions, from the same quarter in 2024.
The fall in the first quarter 2025 Fibrogen Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures jump of 48.17%.

Looking into first quarter 2025 results within Major Pharmaceutical Preparations industry 62 other companies have achieved higher Capital Expenditures growth. While Fibrogen Inc ' s Capital Expenditures meltdown of -46.67% ranks overall at the positon no. 1818 in the first quarter 2025.


FGEN Capital Expenditures ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - -44 % -24.24 % -76.43 %
3rd Quarter September - -88.24 % -21.84 % -44.94 %
2nd Quarter June - -98.99 % 8.79 % -46.47 %
1st Quarter March -46.67 % -94.92 % -64.02 % 215.38 %
FY   - -89.64 % -33.07 % -27.88 %

Financial Statements
Fibrogen Inc 's first quarter 2025 Capital Expenditures $ 0.02 millions FGEN's Income Statement
Fibrogen Inc 's first quarter 2024 Capital Expenditures $ 0.03 millions Quarterly FGEN's Income Statement


FGEN Capital Expenditures (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 75 % -63.24 % -62.07 %
3rd Quarter September - 700 % -31.31 % -4.4 %
2nd Quarter June - -66.67 % 67.8 % -44.51 %
1st Quarter March -88.57 % -88 % 78.79 % 17.14 %
FY (Year on Year)   - -89.64 % -33.07 % -27.88 %


Suppliers by FGEN Divisions >> Back to FGEN Growth rate Comparisons >>


Capital Expenditures first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #202
Overall #1818

Capital Expenditures Y/Y Growth Statistics
High Average Low
879.9 % 48.17 % -89.44 %
(Mar 31 2018)   (Dec 31 2024)
Capital Expenditures first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #63
Healthcare Sector #202
Overall #1818
Capital Expenditures Y/Y Growth Statistics
High Average Low
879.9 % 48.17 % -89.44 %
(Mar 31 2018)   (Dec 31 2024)

Capital Expenditures by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Fibrogen Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
485.71 % 38.89 % -88.65 %
(Sep 30 2024)  


FGEN's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2025 Fibrogen Inc disclosed fall in Capital Expenditures from the fourth quarter by -88.57% to $ 0.02 millions, from $ 0.14 millions achived in the previous reporting period.

But that's not important problem, as Fibrogen Inc 's Capital Expenditures generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 179 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Fibrogen Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2890.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #180
Healthcare Sector #455
Overall #2890
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #180
Healthcare Sector #455
Overall #2890
Capital Expenditures Q/Q Growth Statistics
High Average Low
485.71 % 38.89 % -88.65 %
(Sep 30 2024)  


FGEN's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2025 Fibrogen Inc disclosed fall in Capital Expenditures from the fourth quarter by -88.57% to $ 0.02 millions, from $ 0.14 millions achived in the previous reporting period.

But that's not important problem, as Fibrogen Inc 's Capital Expenditures generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 179 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Fibrogen Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2890.


Fibrogen Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Capital Expenditures 12 Months Ending $ 0.25 $ 0.27 $ 0.38 $ 0.98 $ 1.96
Y / Y Capital Expenditures Growth (TTM) -87.07 % -89.44 % -85.54 % -64.85 % -27.36 %
Year on Year Capital Expenditures Growth Overall Ranking # 1921 # 1867 # 2014 # 2014 # 0
Seqeuential Capital Expenditures Change (TTM) -4.89 % -29.26 % -61.55 % -50.03 % -22.31 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1818 # 1260 # 1279 # 1060 # 0


Cumulative Capital Expenditures growth Comment
Fibrogen Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Dec 31 2024. If the fiscal year would end in Mar 31 2025, Fibrogen Inc 's annual Capital Expenditures fall would be -87.07% year on year to $0 millions.

In the Healthcare sector 208 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 1867 to 1921.

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 63
Healthcare Sector # 209
Overall # 1921

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
879.9 %
 48.17 %
-89.44 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 63
Sector # 202
S&P 500 # 1818
Cumulative Capital Expenditures growth Comment
Fibrogen Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Dec 31 2024. If the fiscal year would end in Mar 31 2025, Fibrogen Inc 's annual Capital Expenditures drop would be -87.07% year on year to $0 millions.

In the Healthcare sector 208 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 1867 to 1921.


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 63
Healthcare Sector # 209
Overall # 1921

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
879.9 %
48.17 %
-89.44 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 63
Sector # 202
S&P 500 # 1818




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
FGEN's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for FGEN's Competitors
Capital Expenditures Growth for Fibrogen Inc 's Suppliers
Capital Expenditures Growth for FGEN's Customers

You may also want to know
FGEN's Annual Growth Rates FGEN's Profitability Ratios FGEN's Asset Turnover Ratio FGEN's Dividend Growth
FGEN's Roe FGEN's Valuation Ratios FGEN's Financial Strength Ratios FGEN's Dividend Payout Ratio
FGEN's Roa FGEN's Inventory Turnover Ratio FGEN's Growth Rates FGEN's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2025
Select Medical Holdings Corp-0.34%$ -0.339 millions
Si bone inc -0.48%$ -0.480 millions
Vaxart Inc -0.76%$ -0.763 millions
Mettler Toledo International Inc-0.78%$ -0.782 millions
Idexx Laboratories Inc-0.82%$ -0.816 millions
Gilead Sciences Inc -0.95%$ -0.952 millions
Johnson and Johnson-1.49%$ -1.487 millions
Iqvia Holdings Inc -2.07%$ -2.069 millions
Cadre Holdings inc -2.53%$ -2.532 millions
Myriad Genetics Inc -3.49%$ -3.488 millions
Irhythm Technologies Inc -3.65%$ -3.652 millions
Becton Dickinson And Company-3.73%$ -3.731 millions
Msa Safety Inc-3.88%$ -3.877 millions
Neurocrine Biosciences Inc -4.46%$ -4.464 millions
Vaxcyte Inc -4.47%$ -4.473 millions
Harvard Bioscience Inc -5.14%$ -5.139 millions
Procept Biorobotics Corporation-5.65%$ -5.653 millions
Labcorp Holdings Inc -5.83%$ -5.830 millions
Crinetics Pharmaceuticals Inc -6.98%$ -6.982 millions
Microbot Medical Inc -7.14%$ -7.143 millions
Maravai Lifesciences Holdings Inc -7.59%$ -7.590 millions
Amneal Pharmaceuticals Inc -8.13%$ -8.128 millions
Bristol myers Squibb Company-8.45%$ -8.451 millions
Community Health Systems Inc -8.60%$ -8.602 millions
Organon and Co -9.38%$ -9.375 millions
Treace Medical Concepts Inc -9.78%$ -9.778 millions
Novocure Limited-9.95%$ -9.954 millions
Revvity Inc-10.43%$ -10.435 millions
Icu Medical Inc-10.68%$ -10.684 millions
Carlisle Companies Incorporated-10.77%$ -10.769 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com